EV Biologics, Inc. (YECO)
OTCMKTS
· Delayed Price · Currency is USD
0.143
-0.058 (-28.75%)
At close: Dec 13, 2024
EV Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2017 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | 2013 - 2012 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '17 Dec 31, 2017 | Dec '17 Dec 31, 2017 | Jun '17 Jun 30, 2017 | Jun '16 Jun 30, 2016 | Jun '15 Jun 30, 2015 | Jun '14 Jun 30, 2014 | 2013 - 2012 |
| Operating Revenue | 9.47 | 9.47 | 9.51 | 42.64 | 46.23 | 44.46 | Upgrade
|
| Other Revenue | 0 | 0 | - | - | - | - | Upgrade
|
| Revenue | 9.47 | 9.47 | 9.51 | 42.64 | 46.23 | 44.46 | Upgrade
|
| Revenue Growth (YoY) | -70.48% | -0.34% | -77.71% | -7.76% | 3.99% | 4.65% | Upgrade
|
| Cost of Revenue | 7.94 | 7.94 | 7.61 | 26.17 | 29.36 | 27.5 | Upgrade
|
| Gross Profit | 1.54 | 1.54 | 1.9 | 16.48 | 16.87 | 16.95 | Upgrade
|
| Selling, General & Admin | 1.38 | 1.38 | 5.83 | 13.29 | 4.01 | 1.74 | Upgrade
|
| Operating Expenses | 1.38 | 1.38 | 5.83 | 13.29 | 4.01 | 1.74 | Upgrade
|
| Operating Income | 0.15 | 0.15 | -3.93 | 3.19 | 12.86 | 15.22 | Upgrade
|
| Interest Expense | -0.58 | -0.58 | -0.66 | -1.03 | -1.3 | -1.18 | Upgrade
|
| Interest & Investment Income | - | - | 0.07 | 0.11 | 0.07 | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | -0.01 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.1 | -0.1 | 0.07 | 0.59 | -0.05 | -0.1 | Upgrade
|
| EBT Excluding Unusual Items | -0.52 | -0.52 | -4.46 | 2.85 | 11.58 | 13.95 | Upgrade
|
| Asset Writedown | - | - | -1.91 | -52.69 | - | - | Upgrade
|
| Other Unusual Items | - | - | -0.79 | - | - | - | Upgrade
|
| Pretax Income | -0.52 | -0.52 | -7.16 | -49.83 | 11.58 | 13.95 | Upgrade
|
| Income Tax Expense | 0.03 | 0.03 | 0.27 | 3.36 | 2.9 | 3.26 | Upgrade
|
| Net Income | -0.55 | -0.55 | -7.43 | -53.19 | 8.68 | 10.69 | Upgrade
|
| Net Income to Common | -0.55 | -0.55 | -7.43 | -53.19 | 8.68 | 10.69 | Upgrade
|
| Net Income Growth | - | - | - | - | -18.82% | 6.40% | Upgrade
|
| Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 2 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 2 | 2 | Upgrade
|
| Shares Change (YoY) | 0.68% | - | 1.02% | 49.09% | - | - | Upgrade
|
| EPS (Basic) | -0.23 | -0.23 | -3.08 | -22.30 | 5.42 | 6.68 | Upgrade
|
| EPS (Diluted) | -0.23 | -0.23 | -3.08 | -22.30 | 5.42 | 6.68 | Upgrade
|
| EPS Growth | - | - | - | - | -18.82% | 6.40% | Upgrade
|
| Free Cash Flow | - | - | -0.38 | -23.34 | 4.19 | 11.27 | Upgrade
|
| Free Cash Flow Per Share | - | - | -0.16 | -9.79 | 2.62 | 7.04 | Upgrade
|
| Gross Margin | 16.24% | 16.24% | 19.94% | 38.64% | 36.49% | 38.13% | Upgrade
|
| Operating Margin | 1.63% | 1.63% | -41.34% | 7.47% | 27.81% | 34.23% | Upgrade
|
| Profit Margin | -5.82% | -5.82% | -78.15% | -124.73% | 18.77% | 24.05% | Upgrade
|
| Free Cash Flow Margin | - | - | -3.99% | -54.74% | 9.05% | 25.35% | Upgrade
|
| EBITDA | - | - | -3.24 | 5.4 | 14.61 | 16.6 | Upgrade
|
| EBITDA Margin | - | - | -34.11% | 12.67% | 31.60% | 37.35% | Upgrade
|
| D&A For EBITDA | - | - | 0.69 | 2.22 | 1.75 | 1.39 | Upgrade
|
| EBIT | 0.15 | 0.15 | -3.93 | 3.19 | 12.86 | 15.22 | Upgrade
|
| EBIT Margin | 1.63% | 1.63% | -41.34% | 7.47% | 27.81% | 34.23% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 25.03% | 23.36% | Upgrade
|
| Revenue as Reported | 9.47 | 9.47 | 9.51 | 42.64 | 46.23 | 44.46 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.